An observational study in Genetic Hemochromatosis, sponsored by Rennes University Hospital. Completed at 6 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Rennes University Hospital · Observational
The purpose of this study is to describe bone status on patients with genetic hemochromatosis, at diagnostic time and his evolution under treatment.
Bone diseases have been recognized recently as complications of genetic hemochromatosis. Further studies are needed to describe the role of iron in bone injuries. The purpose of this study is to describe bone status on patients with genetical hemochromatosis, at diagnostic time and his evolution under treatment.
55 studies on the registry are indexed under Hemochromatosis; 4 are open to participants now.
This study's enrollment of 100 is above the median of 70 across 19 observational studies indexed under Hemochromatosis.
Browse Hemochromatosis studies →Rennes University Hospital is the lead sponsor of 451 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient with genetic hemochromatosis diagnosed in western France hospitals
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bone mineral density
Vertebral and hips Dual energy X-ray Absorptiometry (DXA)
Time frame: Change from baseline in bone mineral density at three years
Predictive value of iron overload on Bone Mineral Density
Time frame: 1 day
Number of vertebral fractures
Time frame: 3 years
Number of peripheral fractures
Time frame: 3 years
Number and location of joint lesions detected by the examination (pain and swelling)
Time frame: 3 years
Determination of genetic polymorphism of BMP 2 and 4
Time frame: Baseline
Ran from Jul 2008 to primary completion in Jun 2014, 71 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.